These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 28871325)

  • 1. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
    Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
    Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
    Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
    Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
    Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
    Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of SIL-2R in Patients with Multiple Myeloma and Its Clinical Significance].
    Lin P; Lin XR; Liu QL; Zhang XY; Chen GW; Xie RT; Zhang YL; DU XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1797-1802. PubMed ID: 36476906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
    Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma].
    Wang Z; Li D; Yang J
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):439-41. PubMed ID: 9387297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
    Umino K; Fujiwara SI; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Lymphoma; 2017 Feb; 58(2):316-323. PubMed ID: 27267694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble interleukin-2 receptor in stage I-III melanoma.
    Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
    Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
    Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
    Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
    Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
    Tozuka T; Yanagitani N; Yoshida H; Manabe R; Ogusu S; Tsugitomi R; Sakamoto H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Seike M; Gemma A; Nishio M
    Invest New Drugs; 2023 Jun; 41(3):411-420. PubMed ID: 37058183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.
    Boyano MD; García-Vázquez MD; Gardeazabal J; García de Galdeano A; Smith-Zubiaga I; Cañavate ML; Raton JA; Bilbao I; Díaz-Pérez JL
    Oncology; 1997; 54(5):400-6. PubMed ID: 9260602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
    Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.